United Therapeutics Corp at Oppenheimer Healthcare Conference Transcript
(technical difficulty)
For joining us here at the United Therapeutics fireside chat. Martine and I would have kept on talking for at least another 10, 15 minutes if we hadn't been told that it's time to go. But I really do appreciate you being here. James also making it down to our conference and looking forward to this fireside chat.
So, Martine, what I thought this time around is we just kind of change things up a little bit and sort of being relentlessly focused on -- when I talk to most companies, I look at sales, I look at earnings and then we talk pipeline.
This time, we talk pipeline. In the last 2 years, you have potentially transformed like UT's pipeline from being heavily dependent on your current commercial products and sort of building them out, right? Each one, sort of, being a core product and you adding more indications and more ways of delivering treprostinil on to them to now looking at different indications; looking at different therapeutic areas, oncology; also looking at sort of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |